Circulating Levels of Dimethylarginines, Chronic Kidney Disease and Long-Term Clinical Outcome in Non-ST-Elevation Myocardial Infarction

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Cavalca, Viviana ^a,b   Veglia, Fabrizio ^a   Squellerio, Isabella ^a   de Metrio, Monica ^a   Rubino, Mara ^a   Porro, Benedetta ^a   Moltrasio, Marco ^a   Tremoli, Elena ^a,b   Marenzi, Giancarlo ^a  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; C REACTIVE PROTEIN; N(G),N(G) DIMETHYLARGININE;

ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REFERENCE VALUE; RISK FACTOR;

AGED; ARGININE; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84869774391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048499     Document Type: Article

References (42)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42: 1050-1065.
2. Go AS, Chertow GM, Fan D, McCullough CE, Hsu C, (2004) Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
3. Herzog CA, Ma JZ, Collins AJ, (1998) Poor-long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339: 799-805.
4. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, et al. (2002) Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137: 563-570.
5. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, et al. (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-562.
6. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Piñero G, et al. (2003) Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 89: 1003-1008.
7. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, et al. (2004) Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. Eur Heart J 25: 1998-2005.
8. Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, et al. (2009) Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 120: 851-858.
9. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, et al. (2010) Acute Coronary Treatment and Intervention Outcomes Network registry. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 121: 357-365.
10. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117.
11. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, et al. (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455.
12. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, et al. (1998) Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction-Its role in hypercholesterolemia. Circulation 98: 1842-1847.
13. Krzyzanowska K, Mittermayer F, Shnawa N, Hofer M, Schnabler J, et al. (2007) Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 24: 81-86.
14. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, et al. (2008) Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31: 747-752.
15. Bode-Böger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, et al. (2006) Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 17: 1128-1134.
16. Fleck C, Schweitzer F, Karge E, Busch M, Stein G, (2003) Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 336: 1-12.
17. Cighetti G, Fermo I, Aman CS, Ferraroni M, Secchi A, et al. (2009) Dimethylarginines in complicated type 1 diabetes: roles of insulin, glucose, and oxidative stress. Free Radic Biol Med 47: 307-311.
18. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, et al. (2008) Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J 29: 2506-2511.
19. Moncada S, Palmer RMJ, Higgs EA, (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-143.
20. Radomski MW, Palmer RM, Moncada S, (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130: 461-470.
22. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney DisSuppl. 1 pp. S1-S246.
23. de Jong S, Teerlink T, (2006) Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 353: 287-289.
24. Marenzi G, Assanelli E, Bartorelli AL, (2006) Management of acute coronary syndromes in patients with renal insufficiency. Current Cardiology Reviews 2: 11-16.
25. Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, et al. (2003) Asymmetric dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22: 23-30.
26. Lu TM, Chung MY, Lin CC, Hsu CP, Lin SJ, (2011) Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 6: 1566-1572.
27. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC, (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24: 1912-1919.
28. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ, (2011) Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 153: 135-140.
29. Maas R, Dentz L, Schwedhelm E, Thoms W, Kuss O, et al. (2007) Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med 35: 1876-1881.
30. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459.
31. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, et al. (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetric dimethylarginine in humans. Circulation 109: 172-177.
32. Bae SW, Stühlinger MC, Yoo HS, Yu KH, Park HK, et al. (2005) Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95: 729-733.
33. Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, et al. (2009) Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis 20: 112-117.
34. Jiang DJ, Cao Y, Xin HY, Li XH, Luo ZQ, et al. (2009) Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 205: 554-560.
35. Meinitzer A, Puchinger M, Winklhofer-Roob BM, Rock E, Ribalta J, et al. (2007) Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 384: 141-148.
36. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D, (2006) Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 21: 2446-2451.
37. Vallance P, Leone A, Calver A, Collier J, Moncada S, (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575.
38. Closs EI, Basha FZ, Habermeier A, Forstermann U, (1997) Interference of L-arginine analogues with L-arginine transport mediated by the y{thorn} carrier hCAT-2B. Nitric Oxide 1: 65-73.
39. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, et al. (1997) Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52: 1593-1601.
40. Al Banchaabouchi M, Marescau B, Possemiers I, D'Hooge R, Levillain O, et al. (2000) NG, NG-dimethylarginine and NG, NG-dimethylarginine in renal insufficiency. Pflugers Arch 439: 524-531.
41. Shemesh O, Golbetz H, Kriss JP, Myers BD, (1985) Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28: 830-838.
42. Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloot S, et al. (2011) Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 6: 2374-2383.